论文部分内容阅读
Objective Although acute myeloid leukemia occurring in patients with Down syndrome (AML-DS)is generally chemosensitive,those patients are more susceptible to regimen-related toxicities,and the optimal post-remission therapy for AML-DS is unknown.This study was aimed to evaluate the outcome of post-remission chemotherapy using low dose cytarabine for AML-DS.